AstraZeneca: collaboration with Champions Oncology.
(CercleFinance.com) - US-based Champions Oncology has signed a strategic collaboration with AstraZeneca to develop novel cohorts of specific PDX models for drug development.
These models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer, said the New Jersey-based company, which specializes in the personalized use of oncology drugs.
The collaboration will enable AstraZeneca to characterize tumor models representing the drug refractory and drug resistant state.
The Patient-Derived Xenograft (PDX) tumor repository enables oncology research questions to be addressed using models that closely resemble human cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
These models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer, said the New Jersey-based company, which specializes in the personalized use of oncology drugs.
The collaboration will enable AstraZeneca to characterize tumor models representing the drug refractory and drug resistant state.
The Patient-Derived Xenograft (PDX) tumor repository enables oncology research questions to be addressed using models that closely resemble human cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.